4//SEC Filing
Harris Erik 4
Accession 0000950170-24-026629
CIK 0001515673other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 8:08 PM ET
Size
10.6 KB
Accession
0000950170-24-026629
Insider Transaction Report
Form 4
Harris Erik
EVP & Chief Commercial Officer
Transactions
- Award
Common Stock
2024-03-01+19,400→ 70,681 total - Award
Common Stock
2024-03-01+957→ 71,638 total - Sale
Common Stock
2024-03-01$53.76/sh−4,768$256,328→ 67,163 total - Award
Stock Option (Right to Buy)
2024-03-01+34,200→ 34,200 totalExercise: $53.69Exp: 2034-03-01→ Common Stock (34,200 underlying)
Footnotes (6)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- [F2]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric.
- [F3]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F4]Includes 293 shares acquired under the Company's Amended & Restated Employee Stock Purchase Plan on October 31, 2023.
- [F5]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F6]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Documents
Issuer
Ultragenyx Pharmaceutical Inc.
CIK 0001515673
Entity typeother
Related Parties
1- filerCIK 0001780113
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 8:08 PM ET
- Size
- 10.6 KB